SNPMiner Trials by Shray Alag

SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT00903292

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression free survival that indicated better efficacy for non-squamous patients treated with pemetrexed. These data supports that pemetrexed could be a preferable chemotherapy drug especially in adenocarcinoma NSCLC patients.

NCT00903292 Non-Small Cell Lung Cancer
MeSH: Carcinoma, Non-Small-Cell Lung Adenocarcinoma Adenocarcinoma of Lung
HPO: Non-small cell lung carcinoma

2 Interventions

Name: erlotinib (Tarceva)

Description: chemotherapy with erlotinib

Type: Drug

A, erlotinib

Name: pemetrexed (Alimta)

Description: Chemotherapy with pemetrexed

Type: Drug

B, pemetrexed

Primary Outcomes

Measure: The primary analysis will be the overall best response rate, including a 95% confidence interval (Leemis and Trivedi 1996).

Time: 02/2009 - 04/2010

Purpose: Screening

Parallel Assignment

There is one SNP


1 L858R

Since typical EGFR gene mutations (i.e., the deletion of typically five amino acids at codons 746-750 (ELREA) in exon 19 and a leucine-to-arginine mutation at codon 858 (L858R)) are a good predictor for tumor response to tyrosine kinase inhibitor, this present study is to tailor the patient's treatment according to his/her EGFR gene mutation status. --- L858R ---

HPO Nodes

Non-small cell lung carcinoma
Genes 2